Corcept Therapeutics will replace Endocrinology President Sean Maduck with Justin Gunn on October 1, while Maduck receives a $57,000 monthly consulting fee. The arrangement matters to investors because Maduck will continue advising executive management during the transition, with his outstanding stock Options continuing to vest under their original schedules.
Key Highlights
- Maduck’s outstanding stock options will keep vesting under their existing schedules during the consulting term.
- Either side can end the consulting arrangement with thirty days’ written notice.
- The agreement initially runs through September 30, 2027, unless terminated earlier.
Corcept Therapeutics Inc (NASDAQ: CORT) is a major pharmaceuticals company. Sean Maduck will leave his position as President of Corcept’s Endocrinology division on October 1, 2026, and Justin Gunn will take over the role. Maduck will remain involved as a senior commercial adviser under a consulting arrangement paying $57,000 per month.
Gunn Takes Over Endocrinology
Maduck informed Corcept’s board of his resignation on September 22, 2026. The company said his departure was not related to any disagreement over operations, financial statements, policies or practices. Gunn will assume his new responsibilities fully on October 1 and join Corcept’s Executive Team.
Advisory Role Supports Handover
The consulting agreement begins on October 1, 2026, and has an initial expiration date of September 30, 2027. Gunn previously built a field sales and Training organisation supporting the launch of Lifyorli, Corcept’s medicine for platinum-resistant ovarian cancer used with nab-paclitaxel. Maduck’s continued service as an adviser is intended to support the changeover, while Corcept thanked him for his contributions and dedication to patients.
FAQs
Q: Who will become Corcept Therapeutics’ Endocrinology president?
A: Justin Gunn will succeed Sean Maduck as President of Corcept’s Endocrinology division. Gunn will fully assume the position on October 1, 2026.
Q: How much will Sean Maduck receive under Corcept’s consulting agreement?
A: Sean Maduck will receive a cash fee of $57,000 per month under his consulting agreement with Corcept Therapeutics. He will advise the chief executive and executive management team.
Q: When does Corcept’s leadership transition take effect?
A: The transition takes effect on October 1, 2026. Sean Maduck’s initial consulting term runs through September 30, 2027, unless the agreement ends earlier.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.